A Double-Blind, Placebo Controlled, Single Ascending Dose Study to Assess the Safety, Tolerability, and Pharmacokinetics of C2N-8E12 in Subjects With Progressive Supranuclear Palsy
Phase of Trial: Phase I
Latest Information Update: 28 Jul 2017
At a glance
- Drugs C2N 8E12 (Primary)
- Indications Progressive supranuclear palsy
- Focus Adverse reactions
- Sponsors C2N Diagnostics
- 20 Jul 2017 Results presented at the Alzheimer's Association International Conference 2017.
- 08 Jun 2017 Results presented at the 21st International Congress of Parkinson's Disease and Movement Disorders.
- 09 Dec 2016 According to a C2N Diagnostics media release, results of this study are guiding the design of phase 2 studies in subjects with Alzheimer's disease (CTP 275868) and progressive supranuclear palsy (CTP 279539).
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History